Eupraxia Pharmaceuticals Inc Ordinary Shares EPRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if EPRX is a good fit for your portfolio.
News
-
Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board
-
Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024
-
Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference
-
Eupraxia Pharmaceuticals Begins Trading on Nasdaq Today
-
Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024
-
Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial Results
-
Toronto Stocks Edge Forward; Shares of Altius Minerals Rise on 4Q Revenue Beat
-
Toronto Stocks Rally; TransAlta Rises on 2Q Profit, Revenue Beat
Trading Information
- Previous Close Price
- CAD 3.72
- Day Range
- CAD 3.76–3.98
- 52-Week Range
- CAD 3.44–9.10
- Bid/Ask
- CAD 3.90 / CAD 3.95
- Market Cap
- CAD 140.35 Mil
- Volume/Avg
- 21,500 / 66,221
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with significant unmet medical needs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 21
- Website
- https://www.eupraxiapharma.com
Comparables
Valuation
|
Metric
|
EPRX
|
ICVX
|
PNT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 11.36 |
Price/Book Value | 48.50 | 3.30 | 3.12 |
Price/Sales | — | — | 5.50 |
Price/Cash Flow | — | — | 13.90 |
Price/Earnings
EPRX
ICVX
PNT
Financial Strength
|
Metric
|
EPRX
|
ICVX
|
PNT
|
|---|---|---|---|
Quick Ratio | 1.01 | 17.59 | 9.01 |
Current Ratio | 1.02 | 18.06 | 9.14 |
Interest Coverage | −24.46 | — | — |
Quick Ratio
EPRX
ICVX
PNT
Profitability
|
Metric
|
EPRX
|
ICVX
|
PNT
|
|---|---|---|---|
Return on Assets (Normalized) | −112.55% | −29.30% | 20.67% |
Return on Equity (Normalized) | −714.09% | −31.87% | 23.56% |
Return on Invested Capital (Normalized) | −123.88% | −34.69% | 23.38% |
Return on Assets
EPRX
ICVX
PNT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Gwwcflkdw | Gyfs | $545.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Zjvpwcw | Rchstd | $105.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Rzbgtlz | Cwrljq | $103.7 Bil | |
MRNA
| Moderna Inc | Tgxxzmfn | Qzyyb | $47.9 Bil | |
ARGX
| argenx SE ADR | Twyrsxpqw | Stzyl | $22.9 Bil | |
BNTX
| BioNTech SE ADR | Lmtnwnqv | Bvbs | $22.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Hlcchzj | Cjkwd | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Rfrgcst | Vbjmp | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Qblnvgwfl | Bvvcmgg | $12.8 Bil | |
INCY
| Incyte Corp | Pntxtllf | Mwdtdvj | $12.1 Bil |